Study of KB004 in Subjects With Hematologic Malignancies

This is a global, multicenter, open-label, repeat-dose, Phase 1/2 study consisting of a Dose Escalation Phase (Phase 1) and a Cohort Expansion Phase (Phase 2). In both phases, KB004 will be administered by IV infusion once weekly as part of a 21-day dosing cycle.

Stanford Investigator(s)


Primary Contact:
Savita Kamble
(650) 723-8594